Evid Invest
Holders — by stockHoldings — by fund

Avidity Partners Management LP

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0001791827

$488.2M

disclosed book value

17

positions

34.3%

largest position share

Positions, as of 2026-09-30

top 18 of 17 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1DNTHDIANTHUS THERAPEUTICS INC1.9M$167.3M34.3%
2CGONCG ONCOLOGY INC1.3M$95.6M19.6%
3ORKAORUKA THERAPEUTICS INC785,424$65.4M13.4%
4CGONCG ONCOLOGY INCCALL850,000$60.3M12.3%
5JBIOJADE BIOSCIENCES INC2.0M$28.1M5.8%
6ELVNENLIVEN THERAPEUTICS INC550,000$25.2M5.2%
7CATXPERSPECTIVE THERAPEUTICS INC6.1M$16.7M3.4%
8AKTSAKTIS ONCOLOGY INC484,200$9.4M1.9%
9IMUXIMMUNIC INC669,941$6.2M1.3%
10MOBIMOBIA MED INC324,676$3.1M0.6%
11PVLAPALVELLA THERAPEUTICS INC NE20,000$2.8M0.6%
12NVCTNUVECTIS PHARMA INC100,415$2.1M0.4%
13MSLESATELLOS BIOSCIENCE INC164,019$1.4M0.3%
14CNTXCONTEXT THERAPEUTICS INC4.1M$1.2M0.2%
15KPTIKARYOPHARM THERAPEUTICS INC884,900$1.1M0.2%
16SENSSENSEONICS HLDGS INC100,000$1.0M0.2%
17SCYXSCYNEXIS INC153,613$758,8480.2%
18AVLNAVALYN PHARMACEUTICALS INC20,000$569,8000.1%

Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.